# Immunovant, Inc. (IMVT)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/immunovant-inc/ JSON: https://steadybase.io/company/immunovant-inc.json Checked Nov 21, 2026. Latest filing read: Nov 9, 2026.

## Company

- Legal name: Immunovant, Inc.
- Ticker: IMVT (Nasdaq)
- SEC CIK: 0001764013
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Durham, NC
- Fiscal year ends: March 31
- SEC filer category: Large accelerated filer
- Website: immunovant.com
- LinkedIn: https://www.linkedin.com/company/immunovant
- Next earnings date: Feb 8, 2027

## Key facts

- Net income: -$505.6M for the fiscal year ended Mar 31, 2026 (10-K filed May 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/0001764013-26-000064-index.html
- SG&A: $76.2M for the fiscal year ended Mar 31, 2026 (10-K filed May 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/0001764013-26-000064-index.html
- Employees: 315 as of Mar 31, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- Shares outstanding: 206,947,758 as of Nov 3, 2026 (10-Q filed Nov 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000122/0001764013-26-000122-index.html
- Auditor: Ernst & Young LLP, Iselin, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm

## Business

Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm

## Officers and directors

- Eric Venker, Chief Executive Officer. Source: Form 4 filed Jul 6, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000077/0001764013-26-000077-index.htm
- Tiago Girao, Chief Financial Officer. Source: Form 4 filed Jul 24, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000161867026000004/0001618670-26-000004-index.htm
- Melanie Gloria, Chief Operating Officer. LinkedIn: https://linkedin.com/in/melanie-gloria-24063032. Source: Form 4 filed Aug 21, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000197383826000007/0001973838-26-000007-index.htm
- Tuyl Christopher Van, Chief Legal Officer. Source: Form 4 filed Sep 25, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000108/0001764013-26-000108-index.htm
- Jay S. Stout, Chief Technology Officer. LinkedIn: https://linkedin.com/in/jay-stout-0b4a365. Source: Form 4 filed Jul 24, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000170296926000010/0001702969-26-000010-index.htm
- Michael Geffner, Chief Medical Officer. Source: Form 4 filed Oct 24, 2025, https://www.sec.gov/Archives/edgar/data/1764013/000176401325000144/0001764013-25-000144-index.htm
- Frank M. Torti, Executive Chairperson of the Board of Directors. Source: 10-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- Andrew Fromkin, Director. Source: 10-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- Atul Pande, Director. Source: 10-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- Douglas Hughes, Director. Source: 10-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- Jacob Bauer, Director. Source: 10-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- Robert Susman, Director. Source: 10-K filed May 20, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- Christopher Van Tuyl, J.D., Named in proxy. Source: DEF 14A filed Jul 22, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000092/imvt-20260721.htm
- Eric Venker, M.D., Pharm.D., Named in proxy. Source: DEF 14A filed Jul 22, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000092/imvt-20260721.htm
- Frank Torti, Board member (per proxy). Source: DEF 14A filed Jul 22, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000092/imvt-20260721.htm
- Tiago Girão, Named in proxy. LinkedIn: https://www.linkedin.com/in/tiagomgirao. Source: DEF 14A filed Jul 22, 2026, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000092/imvt-20260721.htm

## Recent 8-K events

- Nov 9, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/imvt-20261109.htm
- Sep 3, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000106/imvt-20260902.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/imvt-20260806.htm
- May 20, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/imvt-20260520.htm
- Feb 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/imvt-20260206.htm
- Dec 12, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1764013/000119312525317577/d68980d8k.htm
- Dec 11, 2025: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm
- Nov 21, 2025: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000153/imvt-20251121.htm
- Nov 10, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/imvt-20251110.htm
- Sep 3, 2025: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401325000136/imvt-20250903.htm

## Insider trades (Form 4)

- Nov 11, 2026: Atul Pande (Director) sold 3,000 shares, about $108,000. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000126/0001764013-26-000126-index.htm
- Oct 28, 2026: Tiago Girao (Chief Financial Officer) sold 6,606 shares, about $188,271. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000117/0001764013-26-000117-index.htm
- Oct 21, 2026: Jay S. Stout (Chief Technology Officer) sold 2,595 shares, about $75,099. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000114/0001764013-26-000114-index.htm
- Oct 7, 2026: Tuyl Christopher Van (Chief Legal Officer) sold 1,327 shares, about $42,544. Source: https://www.sec.gov/Archives/edgar/data/1764013/000177970726000009/0001779707-26-000009-index.htm
- Oct 7, 2026: Melanie Gloria (Chief Operating Officer) sold 2,241 shares, about $71,846. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000112/0001764013-26-000112-index.htm
- Oct 7, 2026: Jay S. Stout (Chief Technology Officer) sold 3,809 shares, about $122,117. Source: https://www.sec.gov/Archives/edgar/data/1764013/000170296926000012/0001702969-26-000012-index.htm
- Oct 2, 2026: Eric Venker (Chief Executive Officer) sold 3,506 shares, about $119,590. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000110/0001764013-26-000110-index.htm
- Sep 23, 2026: Tuyl Christopher Van (Chief Legal Officer) sold 2,846 shares, about $103,481. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000108/0001764013-26-000108-index.htm
- Aug 28, 2026: Atul Pande (Director) sold 1,500 shares, about $64,905. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000103/0001764013-26-000103-index.htm
- Aug 20, 2026: Melanie Gloria (Chief Operating Officer) sold 3,056 shares, about $134,953. Source: https://www.sec.gov/Archives/edgar/data/1764013/000197383826000007/0001973838-26-000007-index.htm
- Jul 24, 2026: Atul Pande (Director) sold 1,500 shares, about $59,700. Source: https://www.sec.gov/Archives/edgar/data/1764013/000164307126000007/0001643071-26-000007-index.htm
- Jul 23, 2026: Jay S. Stout (Chief Technology Officer) sold 2,857 shares, about $110,537. Source: https://www.sec.gov/Archives/edgar/data/1764013/000170296926000010/0001702969-26-000010-index.htm
- Jul 23, 2026: Tiago Girao (Chief Financial Officer) sold 6,798 shares, about $263,015. Source: https://www.sec.gov/Archives/edgar/data/1764013/000161867026000004/0001618670-26-000004-index.htm
- Jul 8, 2026: Melanie Gloria (Chief Operating Officer) sold 2,036 shares, about $80,532. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000083/0001764013-26-000083-index.htm
- Jul 8, 2026: Tuyl Christopher Van (Chief Legal Officer) sold 1,206 shares, about $47,702. Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000082/0001764013-26-000082-index.htm

## Latest filings

- 8-K filed Sep 3, 2026: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000106/imvt-20260902.htm
- 10-K filed May 20, 2026: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm
- DEF 14A filed Jul 22, 2026: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000092/imvt-20260721.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

